Published • loading... • Updated
Flaura2 Phase III Clinical Study Shows Overall Survival Benefit Trend Consistent with Global Data in Chinese Population Treated with Tagrisso and Chemotherapy for EGFR Mutant Advanced Non-Small Cell Lung Cancer
Summary by chinamoneynetwork.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Flaura2 Phase III Clinical Study Shows Overall Survival Benefit Trend Consistent with Global Data in Chinese Population Treated with Tagrisso and Chemotherapy for EGFR Mutant Advanced Non-Small Cell Lung Cancer
The analysis of overall survival in the Chinese subgroup of FLAURA2 showed that the benefit-risk profile of the combination regimen was consistent with the global cohort. This further confirms that Tagrisso combined with chemotherapy can be a first-line treatment option for Chinese patients with EGFR mutant advanced non-small cell lung cancer. During the 29th National Clinical Oncology Conference and the 2026 CSCO Annual Meeting in Jinan on Sept…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
